bearish
Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement
406 Views03 Dec 2018 08:00
Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) is a biopharmaceutical company which is developing a pipeline of 13 biologic drugs, including...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 8-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Hansoh Pharma IPO Preview: A Decent Story Tarnished by a Huge Pre-IPO Dividend12 Feb 2019
- CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates29 Jan 2019
- Junshi Biosciences IPO Valuation: Sensibly Priced with Upside at the Low-End10 Dec 2018
- Junshi Biosciences IPO Preview: A Sense of Déjà Vu Without the Excitement03 Dec 2018
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
- Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene02 Oct 2018
- BeiGene IPO Preview: Lucrative Lifesavers31 Jul 2018
x